

SDX | SOLUTION
DIAGNOSTICS

January 2024



Empowering personal
healthcare, through
accessible and affordable
solutions.

Summary


We are in discussions with the largest retailers in the US for a rapid antigen test that:

1. Detects Covid-19
2. Detects Flu A
3. Detects Flu B
4. Detects RSV
5. All 4 viruses with 1 swab
6. Rapid Time to Result
7. Easy to Read Result
8. Cost Effective
9. At-Home Use
10. FDA Approved

TAM \$11B

(Covid-19 only tests depicted, doesn't include Flu or RSV)

Total Addressable Market: \$11B USD



And Retailers are willing to pay \$8 Billion for it.

Competition is Inadequate for Market Needs

Test Attributes	Abbot Binax Now	Quidel Quickview	Quest Diagnostics Covid-19 At Home Antigen Test	Cue Covid-19	LabCorp OnDemand Covid-19+Flu+RSV Home Kit	SDX 4SureRapid™
Covid-19	✓	✓	✓	✓	✓	✓
Flu A	✗	✗	✗	✗	✓	✓
Flu B	✗	✗	✗	✗	✓	✓
RSV	✗	✗	✗	✗	✓	✓
At-Home	✓	✓	✓	✓	✓	✓
Time < 15 min	✓	✓	✓	✗	✗	✓
Result On Test	✓	✓	✓	✗	✗	✓
Cost < \$30	✓	✓	✗	✗	✗	✓
FDA Approved	✓	✓	✓	✓	✓	TBD

4SureRapid™ Team



Chiao-ih Hui
CEO

- Technical operations executive with international experience.
- Nearly 30 years of expertise in cradle to grave product development experience.
- Launched over a dozen products globally



Duke Heninger
CFO

- Led the finance team at an Inc. 500 Fastest-Growing Company in the manufacturing space.
- Partner at a large fractional CFO firm.




Marcus Osborne
Advisor


- Previously, served as Senior Vice President of Health Transformation at Walmart.
- Marcus Osborne serves as CEO of RightMove.

How 4SureRapid™ Works

- Step 1: Swab nose
- Step 2: Swirl in Buffer Tube for 1 min, remove
- Step 3: Place test into buffer tube for 15 min
- Step 4: Read results



Business Model



Immediate Retail Sales Channel Forecast



- Forecast during non-illness season:
 - 400 tests / store / month
 - 8.8M tests / month
- Forecast during respiratory illness season:
 - 1200 tests / store / month
 - 26.4M tests / month

Immediate Retail Sales Channel: Private Label



Working with CVS to private-label our test into 9,800+ stores nation-wide **guaranteeing dedicated shelf space in all 9,800+ stores.**

- May - Aug
 - 3.9M tests / month
- Sep – April
 - 11.8M tests / month

2 Key Retailer Use Cases

1. General Wellness Stock Use Case (for Consumers to purchase and use at home)

- At-home first-aid supplies, Tylenol & Ibuprofen, allergy medicine...

2. Pharmacy Play

- Customer convenience to get tested while shopping
- Positive result = additional sales
 - Medication ready
 - Additional products – Gatorade, Tylenol, Kleenex, Mucinex...



<https://corporate.walmart.com/news/2023/08/29/walmarts-new-testing-and-treatment-program-empowers-pharmacists-beyond-the-prescription>

Technical Confidence in Product



- Analytical Testing and current clinical data shows that SDX is on track to exceed FDA requirements
- Received positive FDA feedback regarding our Presubmission
- Confirmed De Novo rather than 510(k)



- Our R&D/Manufacturing Partner:
 - Hold several FDA approvals
 - Investing 50% of all testing and regulatory costs (between \$2-3M USD)
 - Making Capital Investments in added Manufacturing Lines to meet demand



- FDA Market Clearance will be held under Solution Diagnostics = Exclusivity in US

FDA's Positive Response



Response to SDX Presubmission from FDA and Zoom with FDA (Aug 2023):

- Reduced required clinical numbers
- Suggested alternative design of kit
- Branch Chief confirmed first of it's kind (De Novo rather than 510(k))
- Shared acceptable alternative strategies for submission

Milestones Achieved and Expected Timeline


- 4Q23: Completed successful Pivotal Clinical Trial with patients
- 1Q24: Green lighted phased Pivotal Clinical Trial
- 2Q24: Complete Clinical Trials and submit to FDA
- 3Q24: Ramp up production and launch in Retailers
- 4Q24: First payments from Retailers

Financials and Assumptions

- Based upon Walmart and CVS forecasts
- Financial forecast assumes 400 tests/month/store.
- COGS will mostly be PO Financed (already lined up)

PRO-FORMA	2024	2025	2026	2027
Revenue (K)	\$25,600	\$96,000	\$232,000	\$422,400
COGS (K)	\$13,152	\$49,320	\$119,190	\$217,008
Gross Profit (K)	\$12,488	\$46,680	\$112,810	\$205,392
Gross Margin %	48.63%	48.63%	48.63%	48.63%

Use of Funds: \$3M





For More Detailed Info
&
link to our Deal Room

Chiao-ih Hui
Founder & CEO

Chiaoih@solutiondx.com